Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases

NCT00326820 is registered in ClinicalTrials.gov with Wales Cancer Trials Unit as lead sponsor.

NCT NCT00326820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00326820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases
Lead sponsor
Wales Cancer Trials Unit
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2006
Completion date
October 31, 2015
Enrollment
1,404 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hypercalcemia of malignancy, metastatic cancer